UNSPSC 51282928: Marbofloxacin

This classification denotes a quinolone antibiotic with the molecular formula C17H19FN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X09WU898T, chemically known as 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid but generally known as marbofloxacin, which bears US NIH Compound Identifier 60651. European Medicines Agency schedules Marbofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08648MIG.

UNSPSC 51282928 Marbofloxacin, a Commodity code, shows minimal relevant recent state and local procurement activity directly aligned with this veterinary antibiotic classification. Recent opportunities tagged to this code overwhelmingly reflect purchases of human pharmaceuticals, medical supplies, and naloxone rather than marbofloxacin-specific products, suggesting either mis-coding in the sourcing database or extremely limited demand for this specific drug under state and local procurement channels.

State and local agencies posting under this code—including Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—are procuring human emergency response pharmaceuticals, naloxone, medical and first aid supplies, and generic multi-source pharmaceuticals through cooperative purchasing agreements and direct-buy solicitations. The only substantially sourced recent opportunity with a concrete deadline is the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division, an estimated $700,000 contract due March 13, 2026, with a 5 percent SLBE bid discount (not to exceed $10,000). The MMCAP RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, targets manufacturers supplying through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) across multiple state and local jurisdictions, with awards effective July 1, 2026. Absent is any recent procurement explicitly requesting marbofloxacin or other veterinary antibiotics at the state or local government level. Unless your firm supplies human pharmaceuticals, emergency medical consumables, or participates in state cooperative purchasing for generic drugs, this code presents negligible pursuit opportunity in the current market.